Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Humacyte Inc (HUMA)

Humacyte Inc (HUMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 643,302
  • Shares Outstanding, K 119,351
  • Annual Sales, $ 0 K
  • Annual Income, $ -110,780 K
  • EBIT $ -107 M
  • EBITDA $ -99 M
  • 60-Month Beta 1.47
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 147.33% ( -3.98%)
  • Historical Volatility 90.90%
  • IV Percentile 83%
  • IV Rank 63.65%
  • IV High 222.96% on 03/25/24
  • IV Low 14.89% on 12/06/23
  • Put/Call Vol Ratio 0.60
  • Today's Volume 2,496
  • Volume Avg (30-Day) 4,795
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 78,378
  • Open Int (30-Day) 64,807

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.25
  • Number of Estimates 1
  • High Estimate -0.25
  • Low Estimate -0.25
  • Prior Year -0.25
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.51 +19.51%
on 10/17/24
6.34 -14.98%
on 10/02/24
-0.11 (-1.91%)
since 10/01/24
3-Month
4.51 +19.51%
on 10/17/24
8.72 -38.18%
on 08/07/24
-3.23 (-37.47%)
since 08/01/24
52-Week
2.02 +166.83%
on 11/02/23
9.97 -45.94%
on 05/31/24
+3.40 (+170.85%)
since 11/01/23

Most Recent Stories

More News
Humacyte (HUMA) Faces Regulatory Scrutiny as FDA Raises Quality Concerns

Humacyte (HUMA) experienced a decline of 1.94% in its latest trading session, closing at $5.05, which was slightly more than the S&P 500's 1.86% daily loss. Over the past month, Humacyte's shares have...

HUMA : 5.39 (+6.73%)
Insider Sale: Director at Humacyte (HUMA) Sells 1,548 Shares

Kathleen Sebelius, a director at Humacyte ($HUMA), sold 1,548 shares of the company on 09-10-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 3.6% of their...

HUMA : 5.39 (+6.73%)
Humacyte (HUMA) Faces Shareholder Scrutiny After FDA Compliance Issues

Humacyte (HUMA), a biotechnology firm specializing in acellular tissue-engineered vessels, recently encountered significant challenges due to regulatory issues with the U.S. FDA. Following reports of FDA...

HUMA : 5.39 (+6.73%)
Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024

HUMA : 5.39 (+6.73%)
Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEVâ„¢) for AV Access in Hemodialysis on October 31, 2024

HUMA : 5.39 (+6.73%)
Humacyte’s $30 Million Stock Offering Fuels Growth Despite Insider Concerns

Benchmark analyst Bruce Jackson maintained a Buy rating on Humacyte (HUMA) with a price target of $15.00, suggesting a significant upside for the company’s stock. Humacyte shares closed at $5.39 yesterday,...

HUMA : 5.39 (+6.73%)
EXAS : 69.80 (+1.26%)
NEO : 14.00 (+3.02%)
Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024

HUMA : 5.39 (+6.73%)
Humacyte Announces Pricing of $30.0 Million Registered Direct Offering

HUMA : 5.39 (+6.73%)
This Surging Small-Cap Biotech Has One Very High-Profile Investor

Humacyte is a pre-revenue biotech company that has delivered outsized gains to shareholders in 2024. But is the small-cap stock a good buy right now?

HUMA : 5.39 (+6.73%)
Last month, we reported on a suspicious stock trade by a U.S. Senator. The stock has now risen 220% since then.

On April 16th, we reported on a stock trade by Senator Tommy Tuberville that looked suspicious to us. The stock has now risen 220% in the month since then. The stock in question was Humacyte, $HUMA. It's...

HUMA : 5.39 (+6.73%)

Business Summary

Humacyte Inc. is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. Humacyte Inc., formerly known as Alpha Healthcare Acquisition Corp., is based in DURHAM, N.C.

See More

Key Turning Points

3rd Resistance Point 6.07
2nd Resistance Point 5.82
1st Resistance Point 5.61
Last Price 5.39
1st Support Level 5.15
2nd Support Level 4.90
3rd Support Level 4.69

See More

52-Week High 9.97
Fibonacci 61.8% 6.93
Fibonacci 50% 5.99
Last Price 5.39
Fibonacci 38.2% 5.06
52-Week Low 2.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar